-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK launches 3-year cost-savings program to simplify organization, fund R&D push

PUBT·07/28/2026 11:06:30
Listen to the news
GSK launches 3-year cost-savings program to simplify organization, fund R&D push
  • GSK launched a 3-year cost-savings program to simplify the organization, freeing resources to accelerate R&D investment.
  • Savings will be mainly reinvested in late-stage pipeline priorities, with some used to support margins through the 2028-2030 dolutegravir patent expiry.
  • Plans include accelerating 7 key late-stage assets across 18 indications, targeting 20+ phase III trial starts in 2026.
  • GSK will establish a new flagship R&D center on the UK’s Cambridge Biomedical Campus to deepen integration with the local life-sciences ecosystem.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.